Logo
Home
language
Kebijakan Privasi·Ketentuan Layanan

New Zealand joins Australia as the second nation to approve MDMA for PTSD treatment

New Zealand joins Australia as the second nation to approve MDMA for PTSD treatment

New Zealand joins Australia as the second nation to approve MDMA for PTSD treatment
Deputy Prime Minister David Seymour said, "PTSD ruins lives and is difficult to treat," and added that MDMA can be very effective through psychedelic‑assisted therapy. He also noted his support for innovative treatments, recalling his backing of magic‑mushroom approval for severe depression last year.
The Ministry of Health explained that MDMA‑assisted treatment will be combined with psychotherapy, delivered in a controlled clinical setting under an authorized psychiatrist, and patients will not be given the drug to take home. Only people aged 18 or older are eligible.
In the United States, the Food and Drug Administration rejected a request to legalise MDMA for medical use in 2024, saying there was insufficient evidence of safety and efficacy. Currently, U.S. PTSD medication options are limited to two antidepressants that require three months of dosing and show uneven response rates.
The approval highlights a shift toward psychedelic‑assisted therapies and could expand treatment options for people with PTSD worldwide.
0:000:00